Evaxion Biotech A/SEVAX
13F holders, Q1 2024 (March 31)6holders
1famous investor
$3.20avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings. The largest holders were Armistice Capital, LLC ($1.2M), Citadel Advisors ($26K) and Beacon Capital Management, LLC ($16K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $1.2M |
| Exits | 1 | $7K |
Ownership 6 holders
| Armistice Capital, LLC | 0.03% | New | 367,000 | $1.2M |
| Citadel Advisors | 0.00% | New | 8,141 | $26K |
| Beacon Capital Management, LLC | 0.00% | New | 4,863 | $16K |
| JPMorgan Chase & Co. | 0.00% | New | 705 | $2K |
| Rhumbline Advisers | 0.00% | New | 290 | $928 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 30 | $96 |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.